EMA: Draft guideline on core summary of product characteristics for human plasma derived and recombinant coagulation factor VIII products

This guideline describes the information to be included in the summary of product characteristics (SmPC) for human plasma derived and recombinant coagulation factor VIII products, which are indicated for use in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).